Research Article

Early norepinephrine decreases fluid and ventilatory requirements in pediatric vasodilatory septic shock

Suchitra Ranjit, Rajeswari Natraj, Sathish Kumar Kandath, Niranjan Kissoon¹, Balasubramaniam Ramakrishnan², Paul E. Marik³

Aims: We previously reported that vasodilatation was common in pediatric septic shock, regardless of whether they were warm or cold, providing a rationale for early norepinephrine (NE) to increase venous return (VR) and arterial tone. Our primary aim was to evaluate the effect of smaller fluid bolus plus early-NE versus the American College of Critical Care Medicine (ACCM) approach to more liberal fluid boluses and vasoactive-inotropic agents on fluid balance, shock resolution, ventilator support and mortality in children with septic shock. Secondly, the impact of early NE on hemodynamic parameters, urine output and lactate levels was assessed using multimodality-monitoring.

Methods: In keeping with the primary aim, the early NE group (N-27) received NE after 30ml/kg fluid, while the ACCM group (N-41) were a historical cohort managed as per the ACCM Guidelines, where after 40-60ml/kg fluid, patients received first line vasoactive-inotropic agents. The effect of early-NE was characterized by measuring stroke volume variation (SVV), systemic vascular resistance index (SVRI) and cardiac function before and after NE, which were monitored using ECHO + Ultrasound-Cardiac-Output-Monitor (USCOM) and lactates. Results: The 6-hr fluid requirement in the early-NE group (88.9±31.3 to 37.4±15.1ml/kg), and ventilated days [median 4 days (IQR 2.5-5.25) to 1 day (IQR 1-1.7)] were significantly less as compared to the ACCM group. However, shock resolution and mortality rates were similar. In the early NE group, the overall SVRI was low (mean 679.7 dynes/sec/cm5/m2, SD 204.5), and SVV decreased from 23.8±8.2 to 18.5±9.7, p=0.005 with NE infusion suggesting improved preload even without further fluid loading. Furthermore, lactate levels decreased and urine-output improved. Conclusion: Early-NE and fluid restriction may be of benefit in resolving shock with less fluid and ventilator support as compared to the ACCM approach.

Keywords: Critical illness, fluid infusion, morbidity, mortality, norepinephrine, pediatrics, sepsis, septic shock, vasodilatory, venous return

Introduction and Aims

We previously reported that vasodilatation is a predominant feature in 85% of children in septic shock.[1,2] Venodilatation leads to peripheral pooling of blood and relative hypovolemia which, compounded with arteriolar vasodilatation, exacerbates hypotension.[3,4] While liberal fluids and vasoactive agents may be beneficial, overreliance on either may realize short-term gains but...
may increase morbidity.[5-8] Liberal fluids pose greater risks in regions with limited ventilator capabilities. In view of the predominance of vasodilation in our cohort, we hypothesized that a combination of initial fluid bolus of 30 ml/kg plus moderate doses of norepinephrine (NE) 0.05–0.1 mcg/kg/min (to improve arterial tone, restore cardiac preload by its alpha-mediated venoconstriction, and provide modest inotropy)[3,4] would reverse the disordered physiology while limiting positive fluid balance and need for ventilator support.

Our hypothesis is supported by reports in adults in whom vasodilatory septic shock is common and early NE improved preload and cardiac output (CO) without the need for large volume fluid boluses.[9,12] We felt that the adult approach will be beneficial as compared to our previous approach which was based on the American College of Critical Care Medicine (ACCM) guidelines[13] where shock refractory to at least 40–60 ml/kg of fluid was treated with the various inotrope-vasoactive agent(s) depending on the blood pressure (BP) and whether the extremities were cold or warm on clinical examination.[1]

Our study had two broad aims. First, we compared mortality, shock resolution, 6- and 24 h fluid balance, and duration of invasive ventilation between two groups, the prospective early-NE group versus the ACCM-cohort (comprising a previously published cohort who were managed as per the ACCM Guidelines).[1]

The second part compared pre- and post-NE hemodynamic parameters within the early-NE group using multimodal monitoring (MMM), specifically to assess fluid responsiveness (FR) as a surrogate of preload, cardiac function, and systemic vascular resistance (SVR); we also monitored for adverse effects including trends in urine flows and lactate levels.

Methods

Setting
All patients were treated in a 10-bed Pediatric Intensive Care Unit (PICU) of a tertiary referral children’s hospital in Chennai, India, from April 2014 to October 2015.

The Institutional Ethics Committee approved the study protocol and since standard drugs and noninvasive cardiac monitoring were being used, the need for consent was waived.

Patient selection
For the early NE group, consecutive patients aged 1 month to 16 years with presumed infection and unresolved shock after 30 ml/kg fluid were included in the study. The methodology for the ACCM cohort was previously published.[1] Shock was defined according to the ACCM/Pediatric Advanced Life Support (PALS) guidelines for defining severe sepsis.[13]

Exclusions
Our aim was to study effect of early NE on vasodilatory shock; hence, we excluded vasoconstricted shock (based on narrow pulse pressure, defined previously)[1] including dengue shock. We also excluded conditions where NE might cause worsening of circulatory status, i.e., cardiogenic shock, moribund patients including need for CPR. Other exclusions were premorbid conditions including malaria, malnutrition, anemia, and where extended MMM could not be performed within 4 h of shock recognition.

Protocol for septic shock management

- For both groups: At baseline, demographic and clinical data, hemodynamic status (extremity perfusion, mental status, heart rates, and BP), and pediatric risk of mortality scores were entered in a standard datasheet. The first dose of broad-spectrum antibiotic(s) were administered within 1 h of shock recognition, and samples were drawn for relevant cultures, blood gas analyses, and lactate measurements.

Intubation and ventilation were performed for

---

**Figure 1a:** Treatment protocol for limited fluid and early norepinephrine cohort. eMMM: Extended-multimodal-monitoring (physical examination, focused ECHO + USCOM); USCOM: Ultrasound cardiac output monitor; FI: Fluid intolerance (features of fluid overload or pulmonary edema); SVRI: Systemic vascular resistance index; IVC: Inferior vena cava; SVV: Stroke-volume-variation
respiratory insufficiency or for unresolved shock despite 30–40 mL/kg fluid and to facilitate the safe use of sedatives during invasive catheter placement. Patients were ventilated in volume-controlled mode with lung protective strategies (tidal volumes, 6–8 mL/kg).

- For the early-norepinephrine group [Figure 1a]: One of the authors (SR, RN, and SKK) evaluated the patients with unresolved shock after 30 mL/kg fluid, and if there were no exclusions, NE was initiated at 0.05–0.1 mcg/kg/min through a peripheral line. Ultrasound cardiac output monitor (USCOM) monitoring was also performed in addition to MMM. The time between the two consecutive measurements did not exceed 2 h. Peripheral NE infusion was changed to central NE as soon as central access was secured. If shock was unresolved after initial fluid bolus plus NE, further cardiovascular therapy (fluid, inotrope, or pressor) was directed by the findings of MMM.

- For the ACCM cohort [Figure 1b]: Following early stabilization including point-of-care testing, first-hour antibiotics, and respiratory support,[13] at least 40 mL/kg fluids were infused, and inotropes-vasopressors were initiated.[1,13] MMM was performed in order offer customized cardiovascular therapy for those with unresolved shock.

**Multimodal-monitoring**

In both groups, patients with unresolved shock received MMM which included clinical assessment, invasive arterial monitoring, and focused echocardiography. Findings from MMM were used to guide further therapy in both groups. However, in the early-NE group, to study the impact of early NE on the circulation, all patients were additionally monitored using USCOM before and after NE infusion.

Authors (SR, RN, and SKK) were trained and certified in ICU sonology (basic + advanced) and also USCOM as per recommendations.[14] Moreover, to minimize observer variability, the first author (SR), who had the...
most experience in both modalities, evaluated all images. Only those images that were satisfactory in terms of image quality and were accurate in interpretation were included in the study. During the USCOM, sinus rhythm was confirmed, spontaneous breathing was not permitted, and the tidal volumes were increased briefly up to 8 mL/kg provided the plateau pressures did not exceed 30 cm H2O.

Techniques and normal values for USCOM variables are described in the USCOM manual.[15]

**Parameters studied by multimodal monitoring and ultrasound cardiac output monitor**

- Volume status: We used dynamic indices of FR as surrogates of cardiac preload.[16,17] We considered the patient to be fluid responsive if the stroke volume variation (SVV) was >15%, based on pediatric studies.[18]
- Cardiac function: Cardiac function was assessed by focused ECHO described previously[1] and USCOM parameters (for early-NE group) including peak velocity and Smith–Madigan inotropy index (SMII) or inotropy index (INO). The SMII or INO index is calculated by the USCOM software and represents a rapid, accurate, loading-independent index to quantify myocardial contractility that is expressed in watts/m².[19] We also monitored stroke volume index and cardiac index (CI)[15,20]
- Afterload: Vasodilatory versus vasoconstricted shock was determined by pulse pressure and diastolic BP[15] SVRI index (SVRI) was derived by the USCOM software to assess perfusion and lung mechanics before and after NE
- Physical examination: Physical examination was used to assess perfusion and lung mechanics before and after NE
- Tissue perfusion: We monitored lactate trends, and urine flows as surrogates of tissue perfusion.

**Data analysis**

In keeping with our study aims, two broad sets of analyses were performed:

- Early NE versus ACCM cohort: Demographics and outcomes comparing fluid balance, ventilator support, PICU stay, and mortality
- “Before-after NE” intra-group analysis: We compared MMM findings pre- and post-NE to assess SVRI, SVV, and cardiac function among

### Table 1: Spectrum, microbiology, and type of infections in early norepinephrine group and the American College of Critical Care Medicine cohort

<table>
<thead>
<tr>
<th>Spectrum, microbiology, and type of infections</th>
<th>Early NE group (n=27)</th>
<th>ACCM cohort (n=41)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Febrile neutrophilic dermatosis</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Gastrointestinal infection</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>5 (MRSA 2)</td>
<td>4 (MRSA 1)</td>
</tr>
<tr>
<td>Streptococcus species</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Enterococcus</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Acinetobacter</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Candida species</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Gram-negative rods</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Scrub typhus (ELISA)</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Hospital-acquired</td>
<td>11</td>
<td>14</td>
</tr>
<tr>
<td>Community-acquired</td>
<td>18</td>
<td>27</td>
</tr>
<tr>
<td>Imunocompromised (recent/current</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>long-term steroid use, leukemia/</td>
<td></td>
<td></td>
</tr>
<tr>
<td>postbone marrow transplant)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunocompetent</td>
<td>23</td>
<td>35</td>
</tr>
</tbody>
</table>

MRSA: Methicillin-resistant Staphylococcus aureus; ELISA: Enzyme-linked immunosorbent assay; CRBSI: Catheter-related bloodstream infection; NE: Norepinephrine; ACCM: American College of Critical Care Medicine; CAP: Ventilator-associated pneumonia; VAP: Community-acquired pneumonia

### Table 2: Demographics and outcomes between early norepinephrine group and American College of Critical Care Medicine cohort

<table>
<thead>
<tr>
<th>Variables</th>
<th>Early NE group (n=27)</th>
<th>ACCM cohort (n=41)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td>24.3 ±19.04</td>
<td>21.1 ±12.7</td>
<td>0.856</td>
</tr>
<tr>
<td>PRISM</td>
<td>19.9 ±7.8</td>
<td>16.02 ±8.4</td>
<td>0.06</td>
</tr>
<tr>
<td>Number with hypertensive shock at presentation (%)</td>
<td>19 (70.4)</td>
<td>20 (48)</td>
<td>0.09</td>
</tr>
<tr>
<td>0–6 h fluid requirement (mL/kg)</td>
<td>37.4 ±15.1</td>
<td>88.9 ±31.3</td>
<td>0.001*</td>
</tr>
<tr>
<td>24-h positive fluid balance (%)</td>
<td>4.8 ±4.5</td>
<td>9.6 ±3.8</td>
<td>0.001**</td>
</tr>
<tr>
<td>Days on invasive ventilation, median (survivors)</td>
<td>1 (1-1.7)</td>
<td>4 (2.5-5.25)</td>
<td>0.001*</td>
</tr>
<tr>
<td>Mortality (%)</td>
<td>27 (10.2)</td>
<td>30 (7.3)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

ACCM: American College of Critical Care Medicine; PRISM: Pediatric risk of mortality; PICU: Pediatric Intensive Care Unit
“Responders” (partial/complete shock reversal) and “Non-responders” (worsening of perfusion/shock).

Statistical analysis
The results are expressed as mean ± standard deviation (SD) or median (25th to 75th percentile) as appropriate. Both sets of comparisons, Early NE versus ACCM cohort, and Before-after NE intra-group analysis were carried out using paired Student’s t-test or the Wilcoxon signed-rank test as appropriate. P < 0.05 was considered statistically significant.

Results
Fifty-five patients in septic shock were recognized in the ER or PICU, of which 27 patients with vasodilatory shock unresolved after 30 ml/kg were included in the study [Figure 2], and data for 41 patients described previously[1] constituted the ACCM cohort.

American College of Critical Care Medicine cohort versus early-norepinephrine group comparison
There was no difference in baseline demographics or severity among the two groups [Tables 1 and 2]. Regarding early antibiotics, 27/27 patients in the early NE group and 40/41 patients in the ACCM cohort had received the first dose antibiotic(s) within the first hour of shock recognition. All patients received early fluid boluses and had appropriate specimens of cultures drawn, metabolic derangements corrected, and respiratory support initiated. All 27 in the early NE group and 38/41 in the ACCM cohort were intubated and ventilated principally to facilitate safe sedation for line placement or for respiratory insufficiency.

Table 1 shows the spectrum, microbiology, and type of infections among patients in both groups, and Table 2 compares demographics and outcomes between the early NE and ACCM cohort.

Fluid volumes, ventilator support, and Pediatric Intensive Care Unit stay
In addition to the limited 1st hour fluid bolus, the 6-h fluid volumes, and 24-h positive fluid balance were significantly less in the early-NE group, and invasive ventilation and PICU days were also significantly lower [Table 2].

Shock resolution and mortality
Shock resolution was similar and there was no difference in mortality between the groups.

Comparison of hemodynamics before and after norepinephrine in early-norepinephrine group
Table 3a and b compares hemodynamic variables before and after NE among 22 patients who had partial or complete improvement (Responders), and 5 with worsened hemodynamic parameters (Non-responders).

a. SVRI changes: Of a total 27 patients, 17 had cold shock and 10 had warm shock; however, the overall SVRI was low (mean 679.7 dynes/s/cm²/m², SD 204.5), this increased (mean 873.57 dynes/s/cm²/m², SD 199) after NE infusion

b. Intravascular volume changes: The SVV declined significantly along with improved perfusion parameters [Table 2], and 19 (70%) patients did not require any further fluid after the initial 30 ml/kg. Additional small volume boluses were given to 8 patients with unresolved shock who were still fluid responsive with no features of fluid intolerance [Table 3a and b]

c. Cardiac function response to NE depended on the intrinsic contractility. For instance, among 13 patients with hyperdynamic shock, the supranormal ejection fraction (EF) and CI values decreased to within normal range, and shock resolved.

Among 14 patients with septic myocardial dysfunction (SMD), the response to NE was variable. Four patients with mild systolic dysfunction resolved with NE alone, five with moderate SMD showed partial shock resolution and required additional inotropy (dobutamine/epinephrine) for complete recovery.

Five patients manifested severely diminished cardiac function that only became apparent when afterload increased with NE (Non-responders, Table 3b). The unmasking of the severe underlying SMD in these five patients occurred within an hour of NE initiation and manifested as worsening perfusion and respiratory mechanics. The deterioration in cardiac function was confirmed by both ECHO and USCOM. Therapy in all five included rapid addition of more inotropes (epinephrine in four and dobutamine in one) while the NE dose was reduced in two patients and discontinued in three.

Repeat MMM demonstrated improved cardiac function in all five patients, and four were discharged alive.

Lactate and urine output after early-norepinephrine
Lactate trends improved in the responders [Table 3a]. Urine output increased on day-1 in 24/27 patients and by day-3 in another two patients.

Three patients had multiorgan failure (MOF) with acute kidney injury (AKI) requiring renal replacement
therapy (RRT) on day-1, including peritoneal dialysis in one and continuous RRT in two patients. However, the renal function and urine output increased sufficiently such that RRT could be discontinued within 24–48 h in two patients, this included one patient who received NE plus additional vasopressin (VP) for severely depressed SVRI. The third patient continued to be anuric, azotemic, and could not be salvaged.

Shock resolution and mortality
There was no difference in shock resolution or mortality between the ACCM-cohort and Early-NE group, Table 2.

Clinical trajectory in nonsurvivors (both groups)
Of the three nonsurvivors in early-NE group, two with severe burn sepsis had rapid shock resolution with fluid and NE (plus inotropy in one) and were extubated and weaned off vasoactive-inotropes by day-2 and day-3, respectively. However, the patients suffered repeated episodes of bacteremia and MOF; both died 7 and 9 days later. The third nonsurvivor had severe community-acquired pneumonia and died at 28 h of admission of unresolved cold vasoplegic shock with very low SVRI (<400 dynes/s/cm²/m²) that failed to normalize even with high-dose NE, epinephrine, VP, and steroids.

In the ACCM cohort, four patients died, including two with unresolved shock and two with hematological malignancies and overwhelming pulmonary hemorrhage.[1]

Discussion
In this pilot feasibility study, we could demonstrate that, compared to the ACCM cohort, the limited fluid bolus and early-NE approach in pediatric vasodilatory shock was associated with decreased positive fluid balance and days on ventilation, with no change in shock resolution or mortality. Moreover, using USCOM before and after NE, we could show that the overall diminished SVRI increased, SVV decreased, and CI improved in the majority, and the treatment was associated with decreasing lactate levels and increasing urine output suggesting favorable physiologic effects.

We used the modest fluid boluses and early-NE in all 27 cases regardless of whether they were cold or warm, provided they were vasodilated (based on wide pulse pressures); this included 63% with cold shock on clinical examination. This approach is supported by our previous reported experience where 85% of 48 septic shock patients were vasodilated with wide pulse pressure on

### Table 3a: Echocardiogram and ultrasound cardiac output monitor parameters before and after norepinephrine in 22 responders

<table>
<thead>
<tr>
<th>Hemodynamic variable</th>
<th>ECHO, USCOM and lactate values</th>
<th>Pre-NE (n=22)</th>
<th>Post-NE (n=22)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preload/fluid responsiveness</td>
<td>SVV</td>
<td>23.79±8.2</td>
<td>18.5±9.7</td>
<td>0.005*</td>
</tr>
<tr>
<td>Cardiac function</td>
<td>Ejection fraction (%)</td>
<td>61.8±14.7</td>
<td>64.6±11.09</td>
<td>0.045*</td>
</tr>
<tr>
<td></td>
<td>INO</td>
<td>1.6±0.5</td>
<td>1.7±0.5</td>
<td>0.158</td>
</tr>
<tr>
<td></td>
<td>SVI (mL/m²)</td>
<td>49.4±14.5</td>
<td>48.9±14.3</td>
<td>0.698</td>
</tr>
<tr>
<td></td>
<td>CI (L/min/m²)</td>
<td>6.63±1.74</td>
<td>6.3±1.68</td>
<td>0.220</td>
</tr>
<tr>
<td></td>
<td>VPK (m/s)</td>
<td>1.6±0.3</td>
<td>1.6±0.3</td>
<td>0.728</td>
</tr>
<tr>
<td>Afterload</td>
<td>SVRI (dynes/s/cm²/m²)</td>
<td>682.9±224.8</td>
<td>854.8±206.2</td>
<td>0.0001*</td>
</tr>
<tr>
<td>Perfusion</td>
<td>Lactate (mmol/L)</td>
<td>4.9±4.5</td>
<td>3.1±2.7</td>
<td>0.006*</td>
</tr>
</tbody>
</table>

*Significant at 5%; *Two-sided paired t-test. FTc: Flow time corrected; SVI: Stroke volume index; CI: Cardiac index; SVRI: Systemic vascular resistance index; INO: Inotropy; SVV: Stroke volume variation; VPK: Peak velocity; NE: Norepinephrine

### Table 3b: Echocardiogram and ultrasound cardiac output monitor parameters before and after norepinephrine in five nonresponders with severe septic myocardial dysfunction

<table>
<thead>
<tr>
<th>Hemodynamic variable</th>
<th>ECHO, USCOM and lactate values</th>
<th>Pre-NE (n=5)</th>
<th>Post-NE (n=5)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preload/fluid responsiveness</td>
<td>SVV</td>
<td>22 (18-31.5)</td>
<td>18 (11-23.5)</td>
<td>0.104</td>
</tr>
<tr>
<td></td>
<td>FTc (ms)</td>
<td>398 (330.5-409.5)</td>
<td>359 (330-383.5)</td>
<td>0.225</td>
</tr>
<tr>
<td>Cardiac function</td>
<td>Ejection fraction (%)</td>
<td>55 (50-69.5)</td>
<td>40 (25-50)</td>
<td>0.042*</td>
</tr>
<tr>
<td></td>
<td>INO (W)</td>
<td>16 (1.35-1.9)</td>
<td>1.2 (0.79-1.5)</td>
<td>0.043*</td>
</tr>
<tr>
<td></td>
<td>SVI (mL/m²)</td>
<td>43 (39-49)</td>
<td>38 (25.5-41)</td>
<td>0.080</td>
</tr>
<tr>
<td></td>
<td>CI (L/min/m²)</td>
<td>6.7 (5.4-7.9)</td>
<td>4.7 (3.9-6.1)</td>
<td>0.068</td>
</tr>
<tr>
<td></td>
<td>VPK (m/s)</td>
<td>1.7 (1.3-1.9)</td>
<td>1.5 (1.2-1.65)</td>
<td>0.144</td>
</tr>
<tr>
<td>Afterload</td>
<td>SVRI (dynes/s/cm²/m²)</td>
<td>672 (605.5-723)</td>
<td>957 (820.5-1090)</td>
<td>0.043*</td>
</tr>
<tr>
<td>Perfusion</td>
<td>Lactate (mmol/L)</td>
<td>3 (1.5-4.5)</td>
<td>5 (3-9)</td>
<td>0.223</td>
</tr>
</tbody>
</table>

Median and IQR. *Significant at 5% *Wilcoxon signed-rank test. FTc: Flow time corrected; SVI: Stroke volume index; CI: Cardiac index; SVRI: Systemic vascular resistance index; INO: Inotropy index; SVV: Stroke volume variation; VPK: Peak velocity; IQR: Interquartile range
invasive arterial pressure monitoring (including 14/21 with cold shock), corroborating other reports that clinical examination can be unreliable. The pathophysiological rationale of patients with vasodilatory shock presenting with cold shock is provided in excellent reviews.

With regard to hemodynamic comparison pre- and post-NE, we studied the SVRI, FR using SVV, and cardiac function. We demonstrated that the SVRI after 30 ml/kg fluid and before NE infusions was low, reconfirming that vasodilatory shock was predominant and justifying the early-NE-based approach.

Vasodilatory shock in children is not unique to our population and has been reported by others. For instance, Brierley and Peters reported that most patients with hospital-acquired infections had low SVRI-high CI shock and even among the community-acquired infections, 64% had low or normal SVRI, rather than the expected high values for the clinical picture of cold shock. Importantly, many patients were receiving significant doses of vasoactive agents, lending support to the assumption that the true incidence of vasodilatory shock may have been even higher before vasoactive therapy.

With respect to volume status in the early-NE group, the finding that the elevated SVV reduced after NE had important implications, suggesting that NE could mimic the effect of fluid loading by its vasoconstrictor effects; moreover, perfusion also improved in 22/27 responders.

The effects of NE are not always salutary and in a given patient, the CO change is determined by the balance between the augmented preload effects, direct myocardial inotropic and arteriolar vasoconstrictor effects.

Thus, in some patients, the greatly diminished myocardial reserve precludes an increase in CO and hence perfusion can be significantly reduced after fluids and NE administration. Indeed, in our study, while 4 with mild SMD improved with NE alone, 10 patients (37%) with moderate to severe SMD required additional inotropic agents in addition to NE; among these 5 had significant decompensation and underlying severe SMD was “unmasked” (Non-responders); this could be detected by clinical examination and improved with additional inotropes and reduction/cessation of NE dose. That the severely diminished heart function can be effectively masked by the low afterload and revealed following NE-induced vasoconstriction has been previously reported.

Dopamine is the initial vasoactive-inopressor agent suggested in the ACCM-PALS Guidelines, the Indian consensus, and in our previous studies. However, recently it’s use has been questioned with a higher incidence of hospital-acquired infections and mortality with dopamine-versus-epinephrine. Pure vasopressors such as VP may also not be ideal because it can cause reduction in CO and even death due to absent inotropy and increased afterload.

Regarding the safety profile of NE in septic shock, despite concerns of renal ischemia, NE may in fact increase urine output and improve creatinine clearance in hyperdynamic septic shock and is the preferred agent for hypotensive vasodilated patients with AKI.

In our cohort, the improved hemodynamics resulted in reduced lactate levels and improved urine output; the renal function improved sufficiently in two patients that RRT could be discontinued. In addition, the need for less fluid shortens the duration of mechanical ventilation; an important consideration in areas of the world where lack of ventilators can contribute to poor outcomes.

Therefore, we suggest that NE may be the preferred first-line inopressor agent in pediatric vasodilatory septic shock after early limited volume bolus, given its ability to address the deranged pathophysiology by increasing preload, cardiac contractility, coronary perfusion and afterload, and without deterioration in urine flows or lactates.

Strengths

Early NE and limited fluid boluses are both important departures from the standard ACCM Guideline, and to justify that this approach worked and was safe, we used extensive MMM with both ECHO and USCOM. MMM was logistically difficult, challenging, and never previously attempted; however, we designed the methodology acknowledging that each monitoring modality had unique strengths and limitations, and multimodal approach might best provide a more comprehensive hemodynamic picture, especially important when a different approach was attempted.

Further, we could document that NE could indeed mimic fluid loading and minimize the need for infused fluids, thus greatly decreasing time on ventilation and PICU days, and we believe that this finding has important implications that must be explored in larger studies. We also showed that lactate and urine output improved in the majority, thus allaying fears that NE might worsen ischemia.
Limitations and generalizability

We used MMM principally to determine whether early-NE after limited volume resuscitation was safe and effective in pediatric septic shock and also to investigate the impact of NE on volume status, SVRI, and cardiac function. We do not at all suggest that MMM be incorporated in the early-NE algorithm as this will not be generalizable or even practical. However, while early-NE is beneficial in the majority with pediatric vasodilatory shock, in the event that the patient fails to improve or worsens, some form of hemodynamic monitoring depending on local expertise is important to help guide further cardiovascular therapy (fluid, inotrope or pressor).

Conclusions and Clinical Implications of Our Study

In a child with septic shock, the traditional order of therapy is liberal volume loading followed by inotrope-vasoactive infusions dictated by physical examination. We suggest that NE may be considered as a first-choice inopressor after limited fluids in vasodilatory shock (based on wide pulse pressures), as this approach may decrease the volume of fluids needed for resuscitation and the time on ventilator support. Careful bedside monitoring is emphasized to detect deterioration and initiate appropriate inotrope therapy for severely impaired cardiac contractility that may be unmasked with NE.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References


